Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI France ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while iShares MSCI France ETF trades at $45.04. The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWQ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $48.35 |
52-Week Low | $278.09 | $41.43 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWQ trades at $45.04 with no recent price movement, showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $45 with identical support levels, indicating consolidation. Recent European market developments, including ECB rate hikes and geopolitical tensions, create a mixed backdrop for this US-listed European-focused ETF.
The ETF faces headwinds from European economic uncertainty and technical bearish signals, though potential short-squeeze opportunities exist. Key risks include European energy price volatility and geopolitical tensions, while institutional interest in European tech investments may provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
